Gilead Sciences (NASDAQ:GILD)

Biotechnology word cloud

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases ...
Read Full Story »
Cisco logo

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

After a 14-year secular bear market that finally ended when the S&P 500 broke solidly above the 1,600 level in the summer of last year, prompting a move to record ...
Read Full Story »
Disney logo

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Typically midterm election years are good years for the stock market. While there is no guarantee that this year will follow the past, there is a good chance that the ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
health care

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

For a variety of reasons, the cases of chronic hepatitis in the United States have surged dramatically over the past 20 years. Currently, it is estimated that more than 3.2 ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
Biotechnology word cloud

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Biotech stock investing can be a nerve-racking experience for investors, especially if they are focused on the companies that are waiting on some sort of binary event or clinical data ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More

Stocks were firm yet again on Friday morning ahead of the PPI wholesale inflation report. Investors have been trying to decide where to put their money after the recent stock ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More

Stocks were firm on Monday morning, looking to add to the recovery bounce from Friday. Investors have now been given an opportunity to look for stocks that have pulled back ...
Read Full Story »
Comcast-Logo

Oppenheimer Adds 5 Triple-Play Rated Stocks to Buy

The tougher the going gets in the stock market, the more investors want to make very sure they have their bets on companies that have every possible attribute working in ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »
mutual funds

Credit Suisse’s Top Large-Cap Stocks Being Bought by Mutual Funds

Anytime you have a very long, protracted up-move in the stock market, the portfolio managers at the top growth mutual funds usually have to start taking some profits and reallocate ...
Read Full Story »
nasdaq-logo

The 5 Most Heavily Shorted Nasdaq Stocks: Who Bucked the Trend?

Short sellers shied away from four of the top five most shorted stocks on the Nasdaq between the June 30 and July 15 settlement dates. The outlier was Frontier Communications, ...
Read Full Story »
DNA

You Just Won’t Believe Gilead’s Profit Margins

Gilead Sciences Inc. (NASDAQ: GILD) has now reported its second-quarter earnings. The largest biotech by market cap turned in earnings of $2.36 per share ($3.93 billion) on more than a ...
Read Full Story »
Biotechnology word cloud

Top Biotech Earnings Previews for the Week Ahead

Earnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will ...
Read Full Story »